Rxo (RXO) Total Liabilities (2021 - 2026)

Rxo (RXO) has reported Total Liabilities for 6 consecutive years, with $1.8 billion the latest figure, recorded in Q1 2026.

• Total Liabilities for Q1 2026 came in at $1.8 billion, up 2.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 2.45% YoY), and the FY2025 annual result was $1.7 billion, down 3.66% from the prior year.
• Total Liabilities was $1.8 billion for Q1 2026 at Rxo, up from $1.7 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $1.8 billion in Q4 2024 and troughed at -$1.2 billion in Q2 2022.
• Average Total Liabilities over 5 years is $1.2 billion, with a median of $1.4 billion recorded in 2023.
• Year-over-year, Total Liabilities jumped 237.39% in 2023 and declined 15.07% in 2024.
• Over 5 years, Total Liabilities stood at $1.4 billion in 2022, then slipped by 14.75% to $1.2 billion in 2023, then soared by 46.39% to $1.8 billion in 2024, then slipped by 3.66% to $1.7 billion in 2025, then advanced by 1.32% to $1.8 billion in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $1.8 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.6 billion in Q3 2025.